Randomized Double-Blind Placebo-Controlled Trial Evaluating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Phase 3
550
about 2.7 years
18+
16 sites in AZ, CA, CO +11
What this study is about
Researchers are testing whether baricitinib, compared to a placebo, improves neurological function, physical function, quality of life, and other symptoms in people with Long COVID. The trial will last for 983 days and involve approximately 550 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take Baricitinib
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
baricitinib
oral (Oral Tablet)
Secondary: Cognitive participant-reported outcomes using the PROMIS-Cognitive Function-Short Form 8a at 1-, 3-, 6-, and 12-months, Exercise capacity including the 6-minute walk test (6MWT) at 6- and 12-months, General participant-reported outcomes using the PROMIS-29 at 1-, 3-, 6-, and 12-months, Post COVID-19 symptom burden including the Symptom Burden Questionnaire for Long COVID (SBQ-LC) Circulation Subscale at 1-, 3-, 6-, and 12-months, Post-exertional malaise including the modified De Paul Symptom Questionnaire - Post-Exertional Malaise (mDSQ-PEM) at 6- and 12-months, Quality-of-life measures including the EuroQOL-5D-5L at 3-, 6-, and 12-months
Infectious